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This work focuses on the preparation of peripherally acting AChE inhibitors as 
a potential treatment of myasthenia gravis. These compounds could also be used as a pre-
treatment of poisoning by organophosphorus AChE inhibitors. They can occupy the active 
site of an enzyme making it inaccessible for irreversible inhibitors. Compounds used in this 
indication should fulfill these requirements: inhibit efficiently AChE (standards currently used 
in the treatment were chosen for the comparison of the inhibitory efficacy), have selective 
effect on AChE and not to cross the blood-brain barrier in order to lower the possible side 
effects. 
Six series of bisquaternary compounds were prepared. Their inhibitory ability was 
determined in vitro against human erythrocyte or recombinant AChE and human plasmatic 
BChE. According to inhibitory ability values acquired, a structure - activity relationships were 
investigated in every series. A few compounds with significant affinity towards AChE were 
found. These most promising compounds were further examined in kinetic tests and a non-
competitive type of inhibition was confirmed. In the docking studies, many interactions of the 
compounds and amino acid residues in the active site of the enzyme were observed. Three 
compounds were also chosen for in vivo determination of the acute toxicity and the ability to 
work as a pre-treatment against soman poisoning. Compared to prophylactic efficacy of 
pyridostigmine, these compounds however showed no significant tendency to protect AChE 
against organophosphorus inhibitor. No influence on the efficacy of the subsequent antidote 
treatment was either observed. 
 
